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Diabetic cardiomyopathy entails the cardiac injury induced by diabetes independently of any vascular disease or hypertension.
Some transcription factors have been proposed to control the gene program involved in the setting and development of related
processes.Nuclear factor-kappa Bisapleiotropic transcriptionfactorassociatedto theregulation ofmanyheart diseases.However,
thenuclearfactor-kappa Broleindiabetic cardiomyopathyisunder investigation.In thispaper, wereview thenuclearfactor-kappa
Bpathwayanditsroleinseveralprocessesthathavebeen linkedto diabetic cardiomyopathy,such asoxidativestress,inﬂammation,
endothelial dysfunction, ﬁbrosis, hypertrophy and apoptosis.
1.Introduction
Cardiac diseases are the primary cause of death world-
wide and their associated pathologies have their origins
in alterations of gene expression. Though many causes
of cardiac injury have been identiﬁed, the key molecular
mechanisms of their pathogenesis have not been under-
stood. The molecular processes within the cardiac cell are
controlled by transcription factors such as nuclear factor-
kappa B (NF-κB). In many heart diseases there is an
increased NF-κB activity. In particular, NF-κBa c t i v a t i o n
is involved in congestive heart failure, myocardial hyper-
trophy, diabetic cardiomyopathy (DC) and coronary artery
disease, including acute coronary syndromes and ischemic
reperfusion. In this paper we will focus on the potential
role of NF-κB activation in DC. This entity includes the
direct eﬀect of diabetes mellitus, as one of the most
prevalent diseases, on the myocardium. NF-κBa c t i v a t i o n
may act in DC via canonical and non-canonical pathways,
by controlling diﬀerent set of genes and being involved
in related processes such as oxidative stress, inﬂammation,
endothelial dysfunction, ﬁbrosis, hypertrophy and apopto-
sis.
2.NuclearFactor-κBSignaling
NF-κB is a ubiquitous family of inducible dimeric homod-
imer or heterodimer transcription factors including ﬁve
members: Rel (c-Rel), RelA (p65), RelB, NF-κB1(p50/p105)
and NF-κB2(p52/p100). All of these proteins share a highly
conserved Rel homology region of about 300 amino acids,
composed of two immunoglobulin-like domains [1–4].
This region is responsible for the interaction with other
members of the family, inhibitory proteins and DNA. In
non-stimulated cells,homodimers orheterodimersofNF-κB
family members are bound to ankyrin-rich regions of NF-κB
inhibitory proteins (IκB). Thus, the NF-κB-nuclear localiza-
tion sequences are masked, and NF-κB remains sequestered
in the cytoplasm [2, 3]. Among the diﬀerent tissues, two
principal signaling cascades, the classical/canonical NF-κB
activation and the alternative/non-canonical pathway, can
control NF-κB activation and nuclear transport in the heart.
The canonical pathway proceeds via phosphorylation,
ubiquitination, and proteasomal degradation of speciﬁc IκB,
in particular IκBα,I κBβ,I κBε or Bcl-3 (Figure 1(a)). The
phosphorylation occurs at two serines (S32 and S36) in
the aminoterminus of IκBa n di sc a t a l y z e db yI κBk i n a s e s2 Mediators of Inﬂammation
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Figure 1: Canonical and non-canonical NF-κB signalling pathways. (a) The classical NF-κB pathway activation follows a trans-
phosphorylation chain from the speciﬁc activated receptors to the IκB proteins. This triggers NF-κB heterodimer to entry into the nucleus
and control the gene expression by binding to κB sites within promoter regions. (b) In the non-canonical signaling, trans-phosphorylation
and proteasome degradation are needed before active NF-κB can access into the nucleus. TNFR: TNFα receptor; IL1R: IL-1β receptor.Mediators of Inﬂammation 3
(IKKs)-α and mostly β, complexed with the regulatory sub-
unit NEMO (NF-κB essential modulator). Phosphorylation
promotes lysine 48- (K48-) linked polyubiquitination at
adjacent lysine residues initiated by the ubiquitin E3 ligase
complex SCFβTrCp [3]. Ubiquitination leads to proteolysis
of the NF-κB-bound IκB at the 26S proteasome. Thus,
free ubiquitin can be reused for IκBd e g r a d a t i o ns i g n a l -
ing. Free NF-κB dimers, commonly the RelA/NF-κB1(p50)
heterodimer, translocate into the nucleus through interac-
tion with karyopherins (nuclei-cytoplasmic transporters).
Activated NF-κBb i n dN F - κB-DNA sites (named κBs i t e s )
to regulate gene transcription. Interestingly, knockout mice
for all of the NF-κB subunits have been obtained, but
only the RelA knockout is non-viable, suggesting some
functional redundancy among other members of the family
[4].
The non-canonical route starts through the phos-
phorylation, ubiquitination, and proteasomal degradation
of inhibitory NF-κB1(p105) and NF-κB2/p100 proteins
(Figure 1(b)). This pathway is much slower and weaker than
the former and depends on IKKα but not IKKβ or NEMO.
NF-κB1(p105) and NF-κB2/p100 are phosphorylated at
their carboxyl-terminus and then K48-polyubiquitinated by
SCFβTrCp ligase [4]. Subsequent proteasomal processing of
NF-κB1(p105) or NF-κB2/p100 generates mature p50 or
p52, respectively, which heterodimerizes with RelB. Nuclear
translocation of these heterodimers and transcriptional
activation of distinct target genes follow.
IKK complexes appear to be the most likely point
of convergence of many NF-κB regulators. Some NF-κB
inhibitors target IKKs competing for their ATP binding
site, abrogating IκB phosphorylation and degradation, and
thereby NF-κB activation. In this sense, deubiquitinating
e n z y m e ss u c ha sC Y L Da n dA 2 0c a na l s ob l o c kN F -
κB activation by removal of ubiquitinated chains [4, 5].
IKK can even directly phosphorylate RelA subunit, which
increases its transactivation strength [2, 4]. In addition,
IKK-phosphorylated targets, IκBs, play critical roles in the
regulation of NF-κB[ 6]. As an example, the absence of
IKBα in knockout mice produces a lethal increase of skin
inﬂammation and proinﬂammatory molecules [7].
3.NF-κB-RegulatedGenes
NF-κB was initially identiﬁed as a nuclear factor bound
to the enhancer of the immunoglobulin-κ light chain
gene of B-lymphocytes. However, it is clear that several
dozens of NF-κB:IκB complexes may exist within the cells,
providing an enormous diversity of options and allowing
for speciﬁc regulations in the NF-κBs y s t e m .T h u s ,d i ﬀerent
activated NF-κB dimers bind with distinct aﬃnity to a
variety of consensus κB sites in the heart [8]. The κBs i t e s
[5-GGG(A/G)NN(C/T)(C/T)CC-3;w h e r eNi sa n yb a s e ]
can be uneven resulting in subtle cell and gene-speciﬁc
modulations of gene expression. Importantly, NF-κBd i m e r s
do not promote gene transcription by themselves, but as a
part of a complex of several coactivators such as the cAMP
ResponseElementBindingProteinorSignalTransducersand
Adaptors of Transcription [8, 9]. Moreover, NF-κBi n t e r a c t s
Table 1: Potential main stimuli and NF-κB-related genes involved
in DC. Diﬀerent stimuli can activate NF-κB signalling (left) and
several targeted genes (right) may be controlled by NF-κBi nt h e
diabetic heart. COX2: cyclooxygenase-2; Mn2+-SOD: manganese-
superoxide dismutase; IFNγ: interferon-γ;R A N T E S :r e g u l a t e d
upon activation normal T cell expressed and secreted. The rest of
abbreviations are described along the paper.
κB site
genes
NF-κB stimuli NF-κB targeted
Glucose TNFα
TNFα IL-1β
IL-1β IL-6
IL-2 IL-12
IFNγ IFNγ
ROS iNOS
Angiotensin-II Mn2+-SOD
Endothelin-I COX-2
TGFβ ICAM-I
Toll-like receptors VCAM-I
Lipoproteins E-selectin
Anoxia MCP-I
Reoxygenation RANTES
Double-strand RNA Angiotensinogen
BcI-2
IAPs/XIAPs
Metalloproteases
RelB
c-Rel
NFκB1(p105)
IκBα
Ubiquitin-related proteins
Acute-phase proteins
with a variety of other transcription factors in a positive
or negative manner. In some cases, like Nuclear Factor-IL-6
and activator protein-1 (AP-1), the interaction results in
a synergistic stimulation of inﬂammatory genes [1, 3, 10].
On the contrary, the physical association of NF-κBa n d
the glucocorticoid receptor (another transcription factor)
inhibits NF-κB DNA binding (and enhances IκBα levels)
[11]. Peroxisome proliferator activated receptor (PPAR) is
another transcription factor able to avoid the NF-κBn u c l e a r
translocation [12].
NF-κB controls the expression of some 200 target genes.
Many of them are involved in inﬂammation, such as
adhesion molecules, interleukins, chemokines, acute phase
response genes and cytokines [2, 6, 8]. Some of these
cytokines are TNF-α and IL-1β, closing the circle of a
self-sustained loop (Table 1). Also NF-κB regulates a large
number of immune responses, stress, surface receptors,
cell survival, growth factors, proliferation and ubiquitin-
proteosome system genes. Interestingly, the RelB, c-Rel, NF-
κB1(p105) and IκBα gene expression is underNF-κB control
[9].4 Mediators of Inﬂammation
4.NF-κBandDiabetic Cardiomyopathy
Type-I and type-II diabetic patients are at increased risk
of cardiomyopathy and heart failure is a major cause of
death for these patients [13–15]. Two-thirds of the diabetic
patients die because of cardiovascular complications [16]. In
the Framingham heart study, the risk of heart failure was
increased in diabetic men and women by two- and ﬁvefold,
respectively [17]. This could not be explained by looking at
several other diabetes mellitus-associated risk factors such
as obesity, dyslipidemia, infarction, autonomic neuropathy,
or endothelial dysfunction. Thus, diabetes mellitus alters
cardiac structure and function independently of coronary
artery disease and systemic hypertension, a condition known
as diabetic cardiomyopathy (DC) [18]. Here, the associated
hyperglycemia and hyperlipidemia induce severe cardiac
alterations (metabolic and structural) that lead to ventric-
ular diastolic and systolic dysfunction, typically a delayed
relaxation pattern and presence of left atrial enlargement
[19]. However, there is an uncompleted knowledge of the
DC-associated cellular mechanisms [18], including NF-κB
signalling.
NF-κB can be activated by a large number of both phys-
iological and non-physiological stimuli, including cytokines,
mitogens, viruses, mechanical and oxidative stress (Table 1).
However, at present it is unclear how various intracellular
and extracellular stimuli converge to trigger NF-κBa c t i -
vation. Myocardial tissue from patients with heart failure
of various etiologies exhibits activation of NF-κBa n d
overexpression of NF-κB-regulated genes [20]. In DC, the
high concentrations of circulating glucose and LDL/VLDL
lipoproteins stimulate myocardial NF-κBa c t i v a t i o n[ 21, 22].
Also they lead to the release of vasoactive peptides (i.e.,
angiotensin-II, endothelin-1, phenylephrine) and growth
factors (TGFβ, Connective Tissue Growth Factor) from
the circulating and local cells [23–26]. These molecules
could stimulate NF-κBa c t i v i t yd i r e c t l yo rb yc y t o k i n e -
mediated expression (Figure 2). In the canonical pathway,
under potent stimulus such as cytokines (TNFα,I L - 1 β)o r
lipopolysaccharide, IκBα is rapidly degraded within minutes
[9]. TNFα and IL-1β activate NF-κB primarily through
interaction with their respective type-1 receptors, which
bind to adapter molecules such as TNF Receptor-Associated
Factors. Then, these adapters can interact with mitogen-
activated protein- (MAP-) kinase, which transphosphorylate
and activate IKK [8]. In the non-canonical pathway, cellular
receptors such as receptor activator of NF-κB, CD40 and
lymphotoxin-βRs t i m u l a t eN F - κB[ 3]. Other stimuli like
double-stranded RNA result also in NF-κBa c t i v a t i o n[ 27].
In these cases, a common interacting protein (NF-κB
Inducing Kinase) can transphosphorylate to IκBp r o t e i n s
[28].
Most information on pathogenic mechanisms in DC
is derived from animal models [29, 30]. Some in vivo
and in vitro data suggest the NF-κB participation. An
increase of NF-κB activity in a diabetic [10]o rd i a b e t i c -
hypertensive [31] rat heart has been described. In cultured
cardiomyocytes, incubation with high-glucose promotes
NF-κB activation through the diacylglycerol-PKC signal
transduction pathway. This route increased PKCα and
PKCβ2, which phosphorylated MAP-kinase and lately IκB
[22]. The cardiac responses to DC are oxidative stress,
inﬂammation, endothelialdysfunction, ﬁbrosis, hypertrophy
and apoptosis, in which NF-κB could participate.
4.1. NF-κB and DC-Associated Oxidative Stress. Hyper-
glycemia and subsequently generation of advanced glyca-
tion end-products (AGEs) are major promoting sources of
reactive oxygen species (ROS) within the cardiomyocytes
[32]( F i g u r e2). Another cause of ROS accumulation in the
cardiomyocyte can be the excess of mitochondrial oxidation,
mainlyfromfattyaciddegradation(almosttheuniqueorigin
of fuel in DC) [33]. Some ROS, as superoxide, react with
nitric oxide lacking its beneﬁcial signalling action, or are
convertedtohydroxylradical,which damagesproteins,lipids
and DNA. The elevation of free radicals (and AGEs) also
impairs Ca2+ translocation (by Ca2+-pump decrease) and
triggers NF-κB activation, reducing cardiac contractibility
and modifying the overall gene expression program in
the diabetic cardiomyocytes [23, 33]. In particular, PKC-α
and PKC-β2 overexpression may be mediating the NF-κB
activationinducedbyhighcontentofROS[34].Importantly,
as well as hyperglycemia, cytokine stimulation (TNFα,I L -
1β)m a ya c t i v a t eN F - κB via ROS formation [1, 23]. Thus,
oxidative stress will become a common mediator involved in
the initiation and development of the cardiac responses to
DC.
4.2. NF-κB and DC-Related Inﬂammation. The inﬂamma-
tory response is a signiﬁcant process in the progression of
heart failure in DC. Although cardiac inﬂammation is not
present in chronic experimental models of diabetes mellitus
(by the local expression of anti-inﬂammatory and anti-
oxidant molecules), it has been demonstrated as an early
response tothediabetic insult [35,36].Inhumanmyocardial
biopsies or necropsies there is a lack of information showing
local inﬂammatory leukocytes [37]. However, non-speciﬁc
serum inﬂammatory markers such as MCP-1, IL-6, TNFα,
troponin or C-reactive protein, have been linked to cardio-
vascular dysfunction in diabetic patients [38, 39].
NF-κB is clearly one of the most important regulators
of pro-inﬂammatory gene expression. Cardiac cells express
receptors for pro-inﬂammatory cytokines, IL-1β and TNFα
and also contain the IKK complex needed for NF-κB
signal activation [6, 8]. Interestingly, IκBα knockout mice
are born normally, but usually die a few days after birth
because of extensive skin inﬂammation consistent with
persistent NF-κBa c t i v a t i o n[ 40]. In early experimental
models of DC, activation of NF-κB was correlated with
an increased of IL-1β and TNFα [36, 41]. Thus, NF-κB
could lead to or enhance expression of host genes, including
cytokines, leukocyte adhesion molecules, cyclooxygenase-2
and inducible nitric oxide synthase, ending to a positive
feedback loop (Figure 2). In addition, pro-inﬂammatory
cytokinesproducedby macrophages,T-cells and cardiaccells
may exert their actions on cardiomyocytes and ﬁbroblasts
via NF-κBa c t i v a t i o n[ 23, 40].Mediators of Inﬂammation 5
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Although inﬂammation in human cardiac tissue has
not been entirely demonstrated, animal studies indicate
that the presence of leukocytes in the diabetic heart and
NF-κB activation could play a crucial control. Accordingly,
most of the beneﬁcial eﬀects of DC treatments improve
inﬂammatory events and NF-κB alleviation (see later).
4.3. NF-κB and DC-Involved Endothelial Dysfunction. Endo-
thelial dysfunction is primary cause of atherogenesis initia-
tioninthe coronary vasculature that enforcesthe direct dele-
terious eﬀectof diabetes mellitus on the heart. Inﬂammation
plays a central process in the atherosclerosis plaque forma-
tion [42]. Elevation of circulating glucose, ROS, lipoproteins
and cholesterol damages the endothelial cell layer increasing
the attraction and adhesion/rolling/extravasation of inﬂam-
matory cells. Glycosylated lipoproteins may also serve as
inﬂammatory focus. Cytokines (IL-6, TNFα), angiotensin-II
and adhesion molecules (ICAM-1, VCAM-1, E-selectin) are
released from endothelial cells. As a result, more leukocytes
migrate to subendothelial sites of inﬂammation [42]. Once
there, they promote vascular smooth muscle cells attraction
(by chemokines MCP-1 and IL-8) from the media layer and
ﬁbrosis (by collagen deposition), leading to atherosclerotic
plaque formation. The regulation of all these factors by NF-
κB has been well described in human and animal models
[42]. Finally, the stability of the plaque and thrombosis
can depend on the ECM turnover and presence of pro-
thrombotic factors. In this sense, as well as MMPs, NF-κB
also regulates pro-thrombotic genes.
4.4. NF-κB and DC-Linked Fibrosis. In the heart, vasoactive
peptides and growth factors (angiotensin-II, TGFβ) released
in diabetes mellitus can activate NF-κB[ 10]. TGFβ stim-
ulates the synthesis of extracellular matrix (ECM) proteins
including collagens, ﬁbronectin, tenascin and proteoglycans
[43]( F i g u r e2). Interestingly, a close relationship between
TGFβ and NF-κB signaling has been suggested and NF-
κB can also interact with AP-1 to overexpress collagens,
ﬁbronectin and TGFβ, enhancing the ECM accumulation
[10, 44].
Cardiac injury after DC may result in acute loss of a large
number ofmyocardial cellsleadingtotheformationofascar.
In human biopsies, interstitial and perivascular ﬁbrosis were
present in the diabetic heart [37]. In short- and long-term
diabetic models, ﬁbrosis and ﬁbronectin expression were
augmented [35, 36, 41]. Fibronectin is a major component
of the ECM. This glycoproteinpossess in its promoterregion
a speciﬁc sequence to be regulated by NF-κBD N Ab i n d i n g .
Other NF-κB-induced ECM proteins are elastins [45]. Nev-
ertheless, ﬁbroticdepositiondependsonthebalancebetween
ECM proteins and ECM-degradation enzymes. Interstitial
metalloproteases (MMPs) have the ability to completely6 Mediators of Inﬂammation
degrade collagen and most other ECM components. TGFβ
suppresses matrix degradation through down-regulation of
proteinases, such as plasminogen activators and collage-
nases (i.e., MMPs), and increases synthesis of proteinase
inhibitors, such as Plasminogen Activator Inhibitor-1 and
tissue inhibitors of metalloproteases (TIMPs). However,
paradoxically at least MMP-1, 3, and 9 can be also up-
regulated by NF-κB[ 46], and TIMPs are either up or
down-regulated by NF-κBa c t i v i t y[ 47, 48]. Nevertheless the
balance of pro-over anti-ﬁbrotic factors will promote ECM
deposition in DC [29, 30]. The up-regulation of proﬁbrotic
cytokines and deposition of ECM proteins (via NF-κB,
among others) impair contractibility of cardiomyocytes and
lead to cardiac stiﬀness and heart failure progression in
DC.
4.5. NF-κB and DC-Induced Hypertrophy. NF-κBa n di t s
relationship with cardiac hypertrophy are an exciting area
of research. In other hypertrophic cardiomyopathy such as
dilated cardiomyopathy, there was not genotype or allelic
association between a promoter polymorphism [linked to
inactivation of NF-κB1(p50/p105)] and the occurrence of
heart failure. However, this polymorphism may worsen the
onset of the disease by promoting cardiac remodeling [49].
In DC, as initial compensatory response to stress (glucose
osmolarity, ROSoxidation),cardiomyocytesincrease cellular
size through stimulation of contractile proteins like myosins
and overexpression of embryonic genes such as the Atrial
NatriureticPeptide[50].Wepreviouslydemonstratedalsoan
increase of cell size and Atrial Natriuretic Peptide expression
in the rat diabetic heart [35].
NF-κB activation can be necessary and suﬃcient to
induce myocardial hypertrophy via G-Proteins stimulation
[51] or toll-like receptors (TLRs) [52]. The later medi-
ate their cellular responses by PI3K/Akt/mTOR signaling
and stimulation of NFκB( F i g u r e2). In particular, TLR4
up-regulation has been observed in human heart failure
and ischemic hearts, and TLR4-deﬁcient mice showed
reduced cardiac hypertrophy following pressure overload
[52]. Another potential mechanism involved in the cardiac
prohypertrophic NFκB-dependent pathway includes the
MAP-kinases/PPARactivation.Cardiachypertrophyinduced
by angiotensin-II (via MAP-kinases) was attenuated in p50
null mice [53]. In concordance, TNFα-overexpressing mice
with cardiac hypertrophy and TNFα-induced hypertrophic
cardiomyocytes showed reduction of PPARγ coactivator-1α
expression and its targets (PPAR isoforms). Interestingly, by
NF-κB inhibition or incubation with a speciﬁc inhibitor of
p38-MAP-kinase, cardiac hypertrophy and glucose-induced
oxidation were reverted [54, 55]. Thus, the shift in glu-
cose metabolism to fatty acid degradation during cardiac
hypertrophy may be also improved by MAP-kinase and
NF-κB blockade (or PPAR activation). In consonance, we
have preliminary found hypertrophy inhibition in glucose-
treated cardiomyocytes after PPARβ/δ agonist incubation
(unpublished data). Of note, mice lacking the NF-κB
Interacting Protein-1, a repressor of NF-κB, showed a severe
and rapidly progressive dilated cardiomyopathy but not
ventricular hypertrophy [56].
Cardiacremodeling might function as an adaptive mech-
anism toreplacedeadcellsandmaintain theheart contractile
function. However, hypertrophy can be a bona ﬁde apoptosis
trigger since the increase of cytoskeleton proteins is a major
cause of cell stiﬀness, contractile dysfunction and death
[50].
4.6. NF-κB and DC-Associated Apoptosis. Cardiomyocytes
rarely proliferate within the adult heart, and cardiomyocyte
loss plays an essential role in both animal and human DC
[57, 58]. NF-κB signalling can increase the pro-apoptosis
gene expression depending on the stimuli and cellular
context. In particular, NF-κB is required for endoplasmic
reticulum stress-mediated apoptosis [1, 59]. However, NF-
κB is usually cytoprotective. The anti-apoptotic eﬀect of
NF-κB is very likely to be induced by TNFα, although the
genes involved in this action are not well characterized
[60]. Another postulated eﬀector is cardiotrophin-1. This
IL-6 family member activates NF-κBt h r o u g hM A P - k i n a s e s
and Akt to mediate cytoprotective eﬀects in cardiomyocytes
[61]. NF-κB up-regulates also the Inhibitor of Apoptosis
Proteins, X-linked Inhibitor of Apoptosis Proteins, and anti-
apoptotic factors Bcl2 and cFLIP and indirectly prevents
mitochondrial-mediated apoptosis by induction of Mn2+-
superoxide dismutase (an ROS neutralizer) [62–64]. These
data are in concordance with the fact that RelA and
IKK knockout mice die from extensive liver apoptosis
[40].
In DC, we found an increase of apoptosis and pro-
apoptotic factors in the chronic diabetic rat heart [35].
Interestingly, NF-κB was not activated at these stages of the
disease. Other authors found similar results in early DC
models [23, 41]. Activation of caspase cascade may be in
part responsible forNF-κBabrogation.Inthissense,caspase-
8 degrades RIP-kinase, a mediator needed for TNF-induced
NF-κBa c t i v a t i o n[ 3]. Thus, in contrast to the other events,
activation ofNF-κBmay be appropriatetoattenuate theDC-
associated apoptosis.
5.PotentialNF-κB-Based Therapeutic
ApproachesforDC
Since NF-κB plays critical roles in the pathophysiology
of several process of DC, it is plausible that exogenous
modulation of NF-κBa c t i v a t i o nm a yb ee ﬀective to develop
new therapeutic strategies. However, due to NF-κBu b i q u i t y ,
systemic NF-κB inhibitors are likely to have deleterious
side eﬀects, particularly if used for long periods. When the
original or ongoing stimuli for NF-κB activation cannot be
fully controlled, it is still possible to decrease their eﬀects
by interfering with the associated pathways. NF-κB could
be retained inactive in the cytoplasm by the use of drugs
or genetic manipulations in the cardiac cell. Treatment with
speciﬁc inhibitors against the proteasome degradation of IκB
has shown favourable eﬀects in preventing NF-κBa c t i v a t i o n
[65].Downstream, by using immunosuppressive agentssuch
as cyclosporine-A, IκB degradation is attenuated and NF-κB
remains also sequestered in the cytosol [66]. Also, the ther-
apies with anti-oxidants like pyrrolidine dithiocarbamate,Mediators of Inﬂammation 7
v i t a m i n sCo rE ,o rA T Pc o m p e t i t o r sa sa s p i r i nh a v eb e e n
extensively used in heart injury research [67]. Further, once
active NF-κB enters into nucleus, it would be still feasible
to modulate its transcriptional activity by lacking any inter-
active coactivator (i.e., other transcription factors). NF-κB
repression by glucocorticoid receptors (steroids treatment)
has been successfully assayed [11]. Also, genetic delivery of
IκBα and genetic manipulations with small interfering RNA,
oligodeoxynucleotides or dominant negative against IKK
subunits, may be promising strategies for NF-κB lessening
in DC [8]. Lastly, some apparently NF-κB-unrelated agents
show a potential modulation of the NF-κBp a t h w a y .F o r
instance, angiotensin receptor blockers, angiotensin con-
verting enzyme inhibitors and statins, exhibit beneﬁcial
eﬀects in cardiac diseases although neither hypertension nor
hyperlipidemia are present, possibly by NF-κB attenuation
[68].
However, all of these are unselective attempts to block
NF-κBa c t i v a t i o nt h a tm a yb eh a z a r d o u s .M o r e o v e r ,m o s t
of the beneﬁcial eﬀects have been shown for inﬂammation,
but is uncertain the improvement of NF-κB blockers in
otherDC-linked pathologies such as ﬁbrosis, hypertrophy or
apoptosis. It would be crucial to describe each one of the
multiple ways through which NF-κB can become activated
in the diﬀerent responses to DC, and speciﬁc alterations
may be blocked selectively with reduced side eﬀects. In this
regard, we could proﬁt from the anti-apoptotic role of NF-
κB and develop strategies in which anti-apoptotic pathways
can be triggered in cardiomyocytes that are on their way
to apoptosis, like in DC. Also, a further knowledge of the
composition of the NF-κBd i m e r sa n dN F - κB interacting
partners would help to select the appropriate blockade. In
this regard, increasing PPAR proteins, such as the α and β/δ
isoforms, could mitigate the NF-κB actions in the diabetic
heart.
6.Conclusions
Both classical and alternative pathways of NF-κBa c t i v a t i o n
may participate in the deleterious responses of the cardiac
cells to DC. Oxidative stress, inﬂammation, endothelial
dysfunction, ﬁbrosis, hypertrophy and apoptosis seem to be
“attractive” processes for NF-κB gene regulation. Thus, NF-
κB or, preferentially, any of its speciﬁc related pathways may
be of highly interest for pharmaceutical target. A local tissue
deliveryofinhibitorsthattargetaspeciﬁcsubunitorcofactor
of NF-κB or selective pathway(s) that leads to its modulation
may work in DC.
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